L-asparaginase: An effective agent in the treatment of acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 55, Issue 2, 2014, Pages 256-262

  Kumar, Kuldeep ^a   Kaur, Jagjeet ^a   Walia, Shefali ^a   Pathak, Teena ^a   Aggarwal, Diwakar ^a  

^a Multani Mal Modi College Modinagar   (India)

Author keywords

Lymphocytes; Lymphoid leukemia; Myeloma

Indexed keywords

AMMONIA; ASPARAGINASE; ASPARAGINASE MACROGOL; ASPARAGINE; ASPARTIC ACID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLERGIC REACTION; ANAPHYLAXIS; BLOOD CLOTTING DISORDER; CANCER RADIOTHERAPY; CELL DEATH; CENTRAL NERVOUS SYSTEM; CROSS REACTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; EDEMA; ERYTHEMA; HUMAN; HYDROLYSIS; IMMOBILIZATION; IMMUNE RESPONSE; LEUKEMIA REMISSION; LIMB SWELLING; NONHUMAN; PANCREATITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SERUM SICKNESS; TUMOR CELL; URTICARIA; VEIN THROMBOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHEMORADIOTHERAPY; CLINICAL TRIALS AS TOPIC; DRUG HYPERSENSITIVITY; DRUG RESISTANCE, NEOPLASM; HUMANS; POLYETHYLENE GLYCOLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION;

EID: 84903784880     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.803224     Document Type: Review

References (75)

1. Kumar K, Kataria M, Verma N. Plant asparaginase-based asparagine biosensor for leukemia. Artif Cells Nanomed Biotechnol 2012 Sep 19. [Epub ahead of print]
2. Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998;28:97-113. (Pubitemid 28390409)
3. Kidd JG. Regression of transplanted lymphomas induced in-vivo by means of normal guinea pig serum. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. J Exp Med 1953;98:565-582.
4. Broome ID. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. J Exp Med 1963;118:99-120.
5. Dolowy WC, Henson D, Comet J., et al Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer 1966; 19 1813-1819.
6. Campbell HA, Mashburn LT, Boyse E.A., et al Two L-asparaginase from Escherichia coli B. Their separation, purification and anti-tumor activity. Biochemistry 1967;6:721-730.
7. Jackson RC, Handschumacher RE Escherichia coll L-asparaginase. Catalytic subunit and nature. Biochemistry 1970;9:3585-3590.
8. Schwartz JH, Reeves JY, Broome JD Two L-asparaginase from E. coli and their action against tumors. Proc Natl Acad Sci USA 1966;56:1516-1519.
9. Whelan HA, Writson JC Jr. Purification and properties of asparaginase from Escherichia coli B. Biochemistry 1969;8:2386-2393.
10. Ertel IJ, Nesbit ME, Hammond D, et al Effective dose of L-asparaginase for induction of re missionin previously treated children with ALL: a report from Childrens Cancer Study Group. Cancer Res 1979;39:3893-3896. (Pubitemid 10242204)
11. Duval M, Suciu S, Ferster A., et al Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of randomized European Organistion of Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 2002;99:2734-2739. (Pubitemid 34525359)
12. Clavell LA, Gelber RD, Cohen H.J., et al Four-agent induction and intensive L-asparaginase therapy for treatment of childhood ALL. N Eng J Med 1986;315:657-663. (Pubitemid 16055930)
13. Rizzari C, Citterio M, Zucchetti M., et al A pharmalogical study on pegylated asparaginase used in front-line treatment of children with ALL. Haematologica 2006;91:24-31. (Pubitemid 43235382)
14. Veronese FM, Mero A. The impact of PEGylation on biological therapies. Bio Drugs 2008;22:315-329.
15. Pieters R, Hunger SP, Boos J, et al L-asparaginase treatment in ALL: a focus on Erwinia asparaginase. Cancer 2011;117:238-249.
16. Jain R, Zaidi KU, Verma Y, et al L-asparaginase: a promising enzyme for treatment of ALL. People's J Sci Res 2012;5:29-35.
17. Rytting ME. Role of L-asparaginase in ALL: focus in adult patients. Dovepress J 2012;2012:117-124.
18. Apostolidou E, Swords R, Alvarado Y., et al Treatment of ALL: a new era. Drugs 2007;67:2153-2171.
19. Pui CH, Evans WE Treatment of ALL. N Engl J Med 2006;354: 166-178.
20. Schiffer CA. Differences in outcome in adolescents with ALL: a consequence of better regimens? Better doctors? Both? J Clin Oncol 2003;21:760-761. (Pubitemid 46606430)
21. De Bont J.M., Holt B, Dekker AW Significant difference in outcome for adolescents with ALL treated on pediatric vs. adult protocols in the Netherlands. Leukemia 2004;18:2032-2035. (Pubitemid 40028431)
22. Pui CH, Howard SC Current management and challenges of malignant disease in the CNS in paediatric leukemia. Lancet Oncol 2008;9:257-268. (Pubitemid 351722945)
23. Pieters R, Carroll WL Biology and treatment of ALL. Pediatr Clin North Am 2008;55:1-20.
24. Tubergen DG, Gilchrist GS, O'Brien RT, et al Improved outcome with delayed intensification for children with ALL and intermediate presenting features: a Children's Cancer Group phase 3 trial. J Clin Oncol 1993;11:527-537. (Pubitemid 23071052)
25. Moricke A, Zimmermann M, Reiter A., et al Long-term results of five consecutive trials in childhood ALL perfomed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010;24:265-84.
26. Bostrom BC, Sensel MR, Sather H.N., et al Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk ALL: a report from the Children's Cancer Group. Blood 2003;101:3809-3817. (Pubitemid 36857851)
27. Mitchell CD, Richards SM, Kinsey S.E., et al Benefit of dexamethasone compared with prednisone for childhood ALL: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005;129:734-745. (Pubitemid 40904523)
28. Hurwitz CA, Silverman LB, Schorin M.A., et al Substituting dexamethasone for prednisone complicates remission induction in children with ALL. Cancer 2000;88:1964-1969. (Pubitemid 30213008)
29. Vassilios I, Avramls, Sencer S, et al. A randomized comparison of native Escherichia coll asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk ALL: a Children's Cancer Group study. Blood 2002;99:1986-1994. (Pubitemid 34525479)
30. Vrooman LM, Supko JG, Neuberg D.S., et al Erwinia asparaginase after allergy to E. coli asparaginase in children with ALL. Pediatric Blond Cancer 2010:54:199-205.
31. Pullen J, Boyett J, Sinister J., et al Extended triple intrathecal chemotherapy trial for prevention of CNS relapse I good-risk and poor-risk patients with B-progenitor ALL: a Pediatric Oncology Group study. J Clin Oncol 1993;11:839-849. (Pubitemid 23146077)
32. Matloub Y, Bostrom BC, Hunger S.P., et al Escalating intravenous methotrexate improves event-free survival in children with standard-risk ALL: a report from the Children's Oncology Group. Blood 2011;118:243-251.
33. Asselien BL, Dévidas M, Wang C., et al Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood 2011;118:874-883.
34. Ho DH, Brown NS, Yen A, et al Clinical pharmacology of polyethylene glycol-L-asparaglnase. Drug Metab Dispos 1986; 14: 349-352.
35. Vieira Pinheiro J.P., Muller HJ, Schwabe D, et al Drug monitoring of low-dose PEG-ASNase asparaginase (Oncaspar) in children with relapsed ALL. Br J Haematol 2001;113:115-119. (Pubitemid 32423311)
36. Muss HB, Spell N, Scudiery D., et al A phase II trial of PEG-L-asparaglnase in the treatment of non-Hodgldns lymphoma. Invest New Drugs 1990;8:125-130. (Pubitemid 20087258)
37. Ettinger LJ, Kurtzberg J, Voute P.A., et al An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of ALL. Cancer 1995;75:1176-1181.
38. Douer D, Cohen LJ, Peridou L.A., et al Peg-L-Asparaginase (PEG-ASNASE): pharmacokinetics (PK) and clinical response in newly diagnosed adults with ALL treated with multiagent chemotherapy. Blood 1997;90(Suppl. 1):334a.
39. Aguayo A, Cortes J, Thomas D., et al Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated asparaginase, and prednisone in the treatment of patients with refractory or recurrent ALL. Cancer 1999;86:1203-1209. (Pubitemid 29447003)
40. Silverman LB, Gelber RD, Dalton V.K., et al Improved outcome for children with ALL results of Dana-Farber Constorium Protocol 91-01. Blood 2001;97:1211-1218. (Pubitemid 32183741)
41. Moghrabi A, Levy DE, Asselin B, et al Results of Dana-Farber Cancer Institute ALL Constorium Protocol 95-01 for children ALL. Blood 2007;109:896-904. (Pubitemid 46220632)
42. Chakrabarty AK, Friedman H. L-asparaginase induced immunosuppression, effects on antibody forming cells and serum titres. Science 1970;167:869-873.
43. Peterson RG, Handschumacher RG, Mitchell MS Immunological responses to L-asparaginase. J Clin Invest 1971;50:1080-1090.
44. Oettgen HF, Stephenson PA, Schwartz M.K., et al Toxicity of E. coli L-asparaginase in man. Cancer 1970;25:253-278.
45. Killander D, Dohlwitz A, Engstedt L., et al Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 1976;37:220-228.
46. Woo MH, Hak LJ, Storm M.C., et al Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric ALL. Leukemia 1998;12:1527-1533. (Pubitemid 28470435)
47. Fabry U, Korholz D, Jürgens H, et al Anaphylaxis to L-asparaginase during treatment for ALL in children-evidence of a complement-mediated mechanism. Pediatr Res 1985;19:400-408. (Pubitemid 15106664)
48. Nova EK, Phllips AW. L-Glutamineasasubstrate for L-asparaginase from Serratia marcescens. J Bacteriol 1974;117:593-600.
49. Stern ML, Phillips AW, Gottlieb AJ Physical properties of L-asparaginase from Serratia marcescens. J Bacteriol 1976; 125: 719-727.
50. Lubkowski J, Palm GJ, Gilliland G.L., et al Crystal structure and amino acid sequence of Wolinella succinogenes L-asparaginase. Eur J Biochem 1996;241:201.
51. Capizzi RL, Holcenberg JS Asparaginases. In: Holland JF, editor. Cancer Medicine. 2. Philadelphia, PA: Lea & Febiger; 1993. pp. 796-805.
52. Jones B, Holland J. Optimal use of asparaginase in acute lymphocytic leukemia of childhood. Blood 1973;42:1015.
53. Dubashi B, Jain A. L-asparaginase induced cortical venous thrombosis in a patient with acute leukemia. J Pharmacol Pharmcother 2012;3:194-195.
54. Ortega JA, Nesbit ME, Donaldson M.H., et al L-asparaginase, vincristine and prednisone for induction of first remission in acute lymphocytic leukemia. Cancer Res 1977;37:535-540. (Pubitemid 8030402)
55. Haskell CM, Canellos GP, Leventhal BG L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 1969;287:1028-1034.
56. Zubrod CG. The clinical toxicities of L-asparaginase in the treatment of leukemia and lymphoma. Pediatrics 1970;45:555-559.
57. Onuma T, Rosner F, Levy R.N., et al Treatment of adult leukemia with L-asparaginase (NCS 109229). Cancer Chemother Rep 1971; 55:269-275.
58. McLean R, Martin S, Tang L.P., et al Fatal case of L-asparaginase induced pancreatitis. Lancet 1982;2:1401-1402. (Pubitemid 13254809)
59. Capizzi RL. Schedule-dependent synergism and antagonism between methotrexate and asparaginase. Biochem Pharmacol 1974; 23:151-161.
60. Holle LM. Pegasparagase: an alternative? Ann Pharmacother 1997;31:616-624.
61. Sahu S, Saika S, Pai S.K., et al L-asparaginase (leunase) induced pancreatitis in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1998;15:533-538. (Pubitemid 28533816)
62. Redaelli A, Laskin BL, Stephens J.M., et al A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL). Eur J Cancer Care 2005;14:53-62. (Pubitemid 40314386)
63. Faderl S, Jeha S, Kantarjian HM The biology and therapy of adult ALL. Cancer 2003;98:1337-1354.
64. Johnston PG, Hardisty RM, Kay H.E., et al Myelosuppressive effect of colaspase (L-asparaginase) in initial treatment of ALL. Br Med J 1974;3:81-83.
65. Müller H. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998;28:97-113. (Pubitemid 28390409)
66. Allas S et al. Immunogenicity profile in mice of a PEGylated recombinant Erwinia chrysanthemi-derived L-asparaginase. Blood 2009;114(Suppl. 1): Abstract 2034.
67. Capizzi RL. Asparaginase revisited. Leuk Lymphoma 1993;10: 147-159.
68. Tiwari N, Dua RD Purification and preliminary characterization of L-asparaginase from Erwinia aroideae. Indian J Biochem Biophys 1996;33:371-376. (Pubitemid 126337095)
69. Ichimura K. Method for enzyme immobilization. US Pat 4269941; 1981.
70. Balcao VM, Mateo C, Fernandez L., et al Structural and functional stabilization L-asparaginase via multi-subunit immobilization onto highly activated supports. Biotechnol Prog 2001;17:537-542. (Pubitemid 32532783)
71. Schrappe M, Reiter A, Ludwig W.D., et al Improved outcome in childhood ALL despite reduced use of anthracyclines and cranial radiotherapy: results of trail ALL-BFM 90. Blood 2000;95:3310-3322. (Pubitemid 30428458)
72. Pession A, Valsecchi MG, Masera G, et al Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood ALL. Am Soc Clin Oncol 2005;23: 7161-7167.
73. Moricke A, Reiter A, Zimmermann M., et al Risk-adjusted therapy of ALL can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008;111:4477-4489.
74. Storring JM, Minden MD, Kao S, et al Treatment of adults with BCR-ABL negative ALL with a modified pediatric regimen. Br J Haematol 2009;146:76-85.
75. Bassan R, Hoelzer D. Modern therapy of ALL. Am Soc Clin Oncol 2011;29:532-543.